effect overlay
activetrials
Multiple sclerosis
Multiple Sclerosis
B-cell Repopulation

B-cell repopulation in patients with multiple sclerosis treated with anti-CD20 therapies
 

HREC: 2023.079
Principal Investigator: Prof Tomas Kalincik
Coordinator contact:
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
ANZ NMO Collaboration

Prevalence and incidence study of neuromyelitis optica in Australia and New Zealand with population based sensitivity and specificity of NMO IgG antibody positivity
 

HREC: 2010.278
Principal Investigator: Dr Mark Marriott
Coordinator contact:
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
INTREPID

Biomarkers of motor performance in multiple sclerosis: 7T MRI study
 

HREC: 2015.144
Principal Investigator: Prof Trevor Kilpatrick
Coordinator contact: Dr Vivien Li
Funding: Non-Commercial
Multiple sclerosis
Multiple Sclerosis
PASS

A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
 

HREC: 2015.153
Principal Investigator: Dr Mark Marriott
Coordinator contact: Lisa Taylor
Funding: Commercial
Multiple sclerosis
Multiple Sclerosis
MS Reactor

Prospective clinic and home-based serial monitoring of cognition in relapsing- remitting multiple sclerosis
 

HREC: 2015.174
Principal Investigator: Prof Tomas Kalincik
Coordinator contact: Dr Anneke van der Walt
Funding: Non-Commercial